CTIM-35. INB-400 PHASE 1B/2 DRUG RESISTANT IMMUNOTHERAPY WITH ACTIVATED, GENE MODIFIED ALLOGENEIC OR AUTOLOGOUS ΓΔ T CELLS IN COMBINATION WITH MAINTENANCE TEMOZOLOMIDE RECURRENT OR NEWLY DIAGNOSED GLIOBLASTOMA - Goswami, Trishna; Lamb, Lawrence; Rochlin, Kate; Nabors, Burt (Neuro-oncology (Charlottesville, Va.), 2023)
Keywords: Clinical Trials: Immunologic